Cargando…

Impact of the COVID-19 Pandemic on Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Japan

Anti-vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME) improves visual acuity. However, repeated injections during routine outpatient visits are required to maintain this effect. The recent sudden global outbreak of coronavirus disease 2019 (COVID-19) had a major imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Komori, Ryohei, Takamura, Yoshihiro, Yamada, Yutaka, Morioka, Masakazu, Matsubara, Hisashi, Hirano, Takao, Mitamura, Yoshinori, Shimizu, Miho, Kusuhara, Sentaro, Murakami, Tomoya, Nihei, Ryotaro, Ueda, Tetsuo, Kunikata, Hiroshi, Jujo, Tatsuya, Terasaki, Hiroto, Nagasato, Daisuke, Noda, Kousuke, Osaka, Rie, Nagai, Kazuki, Yoshida, Shigeo, Nozaki, Miho, Noma, Hidetaka, Ishigooka, Gaku, Takahashi, Aya, Sawada, Osamu, Kimura, Kazuhiro, Inatani, Masaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696996/
https://www.ncbi.nlm.nih.gov/pubmed/36431271
http://dx.doi.org/10.3390/jcm11226794
_version_ 1784838449324359680
author Komori, Ryohei
Takamura, Yoshihiro
Yamada, Yutaka
Morioka, Masakazu
Matsubara, Hisashi
Hirano, Takao
Mitamura, Yoshinori
Shimizu, Miho
Kusuhara, Sentaro
Murakami, Tomoya
Nihei, Ryotaro
Ueda, Tetsuo
Kunikata, Hiroshi
Jujo, Tatsuya
Terasaki, Hiroto
Nagasato, Daisuke
Noda, Kousuke
Osaka, Rie
Nagai, Kazuki
Yoshida, Shigeo
Nozaki, Miho
Noma, Hidetaka
Ishigooka, Gaku
Takahashi, Aya
Sawada, Osamu
Kimura, Kazuhiro
Inatani, Masaru
author_facet Komori, Ryohei
Takamura, Yoshihiro
Yamada, Yutaka
Morioka, Masakazu
Matsubara, Hisashi
Hirano, Takao
Mitamura, Yoshinori
Shimizu, Miho
Kusuhara, Sentaro
Murakami, Tomoya
Nihei, Ryotaro
Ueda, Tetsuo
Kunikata, Hiroshi
Jujo, Tatsuya
Terasaki, Hiroto
Nagasato, Daisuke
Noda, Kousuke
Osaka, Rie
Nagai, Kazuki
Yoshida, Shigeo
Nozaki, Miho
Noma, Hidetaka
Ishigooka, Gaku
Takahashi, Aya
Sawada, Osamu
Kimura, Kazuhiro
Inatani, Masaru
author_sort Komori, Ryohei
collection PubMed
description Anti-vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME) improves visual acuity. However, repeated injections during routine outpatient visits are required to maintain this effect. The recent sudden global outbreak of coronavirus disease 2019 (COVID-19) had a major impact on daily life, including medical care, such as the provision of VEGF therapy. We retrospectively investigated the relationship between the number of anti-VEGF injections for DME and the number of new COVID-19-positive patients at 23 centers in Japan. We also surveyed ophthalmologists regarding the impact of the COVID-19 pandemic on anti-VEGF therapy. In the third and fourth waves of the pandemic, when the number of infected patients increased, the number of injections significantly decreased. In the first, third, and fourth waves, the number of injections increased significantly during the last month of each wave. Approximately 60.9% of ophthalmologists reported that the number of injections decreased after the pandemic. Of the facilities, 52.2% extended the clinic visit intervals; however, there was no significant difference in the actual number of injections given between before and after the pandemic. Although the number of injections temporarily decreased, Japanese ophthalmologists maintained the total annual number of anti-VEGF injections for DME during the pandemic.
format Online
Article
Text
id pubmed-9696996
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96969962022-11-26 Impact of the COVID-19 Pandemic on Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Japan Komori, Ryohei Takamura, Yoshihiro Yamada, Yutaka Morioka, Masakazu Matsubara, Hisashi Hirano, Takao Mitamura, Yoshinori Shimizu, Miho Kusuhara, Sentaro Murakami, Tomoya Nihei, Ryotaro Ueda, Tetsuo Kunikata, Hiroshi Jujo, Tatsuya Terasaki, Hiroto Nagasato, Daisuke Noda, Kousuke Osaka, Rie Nagai, Kazuki Yoshida, Shigeo Nozaki, Miho Noma, Hidetaka Ishigooka, Gaku Takahashi, Aya Sawada, Osamu Kimura, Kazuhiro Inatani, Masaru J Clin Med Article Anti-vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME) improves visual acuity. However, repeated injections during routine outpatient visits are required to maintain this effect. The recent sudden global outbreak of coronavirus disease 2019 (COVID-19) had a major impact on daily life, including medical care, such as the provision of VEGF therapy. We retrospectively investigated the relationship between the number of anti-VEGF injections for DME and the number of new COVID-19-positive patients at 23 centers in Japan. We also surveyed ophthalmologists regarding the impact of the COVID-19 pandemic on anti-VEGF therapy. In the third and fourth waves of the pandemic, when the number of infected patients increased, the number of injections significantly decreased. In the first, third, and fourth waves, the number of injections increased significantly during the last month of each wave. Approximately 60.9% of ophthalmologists reported that the number of injections decreased after the pandemic. Of the facilities, 52.2% extended the clinic visit intervals; however, there was no significant difference in the actual number of injections given between before and after the pandemic. Although the number of injections temporarily decreased, Japanese ophthalmologists maintained the total annual number of anti-VEGF injections for DME during the pandemic. MDPI 2022-11-16 /pmc/articles/PMC9696996/ /pubmed/36431271 http://dx.doi.org/10.3390/jcm11226794 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Komori, Ryohei
Takamura, Yoshihiro
Yamada, Yutaka
Morioka, Masakazu
Matsubara, Hisashi
Hirano, Takao
Mitamura, Yoshinori
Shimizu, Miho
Kusuhara, Sentaro
Murakami, Tomoya
Nihei, Ryotaro
Ueda, Tetsuo
Kunikata, Hiroshi
Jujo, Tatsuya
Terasaki, Hiroto
Nagasato, Daisuke
Noda, Kousuke
Osaka, Rie
Nagai, Kazuki
Yoshida, Shigeo
Nozaki, Miho
Noma, Hidetaka
Ishigooka, Gaku
Takahashi, Aya
Sawada, Osamu
Kimura, Kazuhiro
Inatani, Masaru
Impact of the COVID-19 Pandemic on Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Japan
title Impact of the COVID-19 Pandemic on Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Japan
title_full Impact of the COVID-19 Pandemic on Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Japan
title_fullStr Impact of the COVID-19 Pandemic on Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Japan
title_full_unstemmed Impact of the COVID-19 Pandemic on Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Japan
title_short Impact of the COVID-19 Pandemic on Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Japan
title_sort impact of the covid-19 pandemic on anti-vascular endothelial growth factor therapy for diabetic macular edema in japan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696996/
https://www.ncbi.nlm.nih.gov/pubmed/36431271
http://dx.doi.org/10.3390/jcm11226794
work_keys_str_mv AT komoriryohei impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT takamurayoshihiro impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT yamadayutaka impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT moriokamasakazu impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT matsubarahisashi impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT hiranotakao impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT mitamurayoshinori impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT shimizumiho impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT kusuharasentaro impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT murakamitomoya impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT niheiryotaro impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT uedatetsuo impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT kunikatahiroshi impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT jujotatsuya impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT terasakihiroto impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT nagasatodaisuke impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT nodakousuke impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT osakarie impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT nagaikazuki impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT yoshidashigeo impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT nozakimiho impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT nomahidetaka impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT ishigookagaku impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT takahashiaya impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT sawadaosamu impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT kimurakazuhiro impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan
AT inatanimasaru impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan